CP-673451: A Selective PDGFRα/β Inhibitor for Cancer Research

Executive Summary: CP-673451 is a potent ATP-competitive inhibitor targeting PDGFRα and PDGFRβ, with IC₅₀ values of 10 nM and 1 nM, respectively, and high selectivity over other receptor tyrosine kinases (APExBIO). In rat C6 glioblastoma xenograft models, oral administration reduces PDGFR-β phosphorylation by over 50% for four hours and inhibits angiogenesis by 70–90% (Pladevall-Morera et al., 2022). CP-673451 demonstrates >180-fold selectivity over c-Kit in cellular assays at nanomolar concentrations. Its use in ATRX-deficient high-grade glioma models reveals increased sensitivity, supporting its role in precision oncology. The compound is supplied by APExBIO as SKU B2173 and is primarily used to probe PDGFR signaling, angiogenesis inhibition, and tumor growth suppression.

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are transmembrane receptor tyrosine kinases central to cell proliferation, angiogenesis, and tumor microenvironment modulation (Pladevall-Morera et al., 2022). Dysregulation and amplification of PDGFRs are frequently observed in diverse malignancies, notably glioblastoma and other high-grade gliomas. ATRX mutations, common in these tumors, correlate with increased PDGFR signaling dependency (Pladevall-Morera et al., 2022). Inhibition of PDGFR kinase activity disrupts downstream signaling cascades required for tumor angiogenesis and survival.

CP-673451 was developed to provide selective, potent inhibition of PDGFRα and PDGFRβ, minimizing off-target effects on kinases such as VEGFR, EGFR, and c-Kit. Its selectivity enables researchers to attribute observed cellular or organismal phenotypes to PDGFR blockade, a significant advantage in dissecting complex oncogenic pathways (internal article—this article updates previous coverage with new benchmarks in ATRX-deficient models).

Mechanism of Action of CP-673451

CP-673451 operates as an ATP-competitive inhibitor, binding to the kinase domain of PDGFRα and PDGFRβ and preventing ATP from engaging the active site (APExBIO). This blocks receptor autophosphorylation and subsequent activation of downstream signaling pathways, such as PI3K/AKT and MAPK/ERK. In vitro, CP-673451 exhibits IC₅₀ values of 10 nM for PDGFRα and 1 nM for PDGFRβ. Selectivity assays demonstrate that at concentrations up to 1 μM, inhibition of VEGFR-2, TIE-2, EGFR, and Lck is negligible, while c-Kit is inhibited only at micromolar concentrations (IC₅₀ = 1.1 μM).

Cell-based studies confirm functional inhibition: in PAE-β (porcine aortic endothelial) cells, CP-673451 inhibits PDGFR-β phosphorylation with an IC₅₀ of 6.4 nM, demonstrating functional potency in cellular context. In H526 cells, the compound shows over 180-fold selectivity over c-Kit, further supporting its utility in models where c-Kit activity may confound results (internal link—this article extends on selectivity data with additional cell line validation).

Evidence & Benchmarks

• CP-673451 inhibits PDGFRα with an IC₅₀ of 10 nM and PDGFRβ with an IC₅₀ of 1 nM in biochemical assays (APExBIO).
• In cellular assays, CP-673451 blocks PDGFR-β phosphorylation in PAE-β cells with an IC₅₀ of 6.4 nM (APExBIO).
• Demonstrates >180-fold selectivity over c-Kit in H526 cell assays, minimizing off-target effects (APExBIO).
• Oral dosing at 50 mg/kg in rat C6 glioblastoma xenograft models reduces PDGFR-β phosphorylation by >50% for four hours (Pladevall-Morera et al., 2022).
• Suppresses PDGF-BB-induced angiogenesis by 70–90% in mouse sponge angiogenesis models (Pladevall-Morera et al., 2022).
• Inhibits tumor growth and reduces microvessel density in xenograft models including Colo205, LS174T, H460, and U87MG (Pladevall-Morera et al., 2022).
• ATRX-deficient high-grade glioma cells are more sensitive to PDGFR inhibition by CP-673451 (Pladevall-Morera et al., 2022).
• CP-673451 is insoluble in water, but soluble in DMSO (≥20.9 mg/mL) and ethanol (≥2.39 mg/mL with warming/sonication), allowing for flexible formulation (APExBIO).
• Recommended storage is -20°C; DMSO stock solutions are stable for several months below -20°C (APExBIO).

This article clarifies the robust in vivo efficacy benchmarks compared to previous summaries by providing updated preclinical model data and selectivity profiles.

Applications, Limits & Misconceptions

CP-673451 is primarily deployed in preclinical cancer research to investigate PDGFR signaling, angiogenesis, and tumor microenvironment modulation. It is particularly valuable in models of glioblastoma and high-grade glioma, especially those with ATRX mutations, as these exhibit increased sensitivity to PDGFR inhibition (Pladevall-Morera et al., 2022). The compound is also used for angiogenesis inhibition assays, tumor growth suppression studies in xenograft models, and mechanistic dissection of tyrosine kinase signaling. Compared to other PDGFR inhibitors, its high selectivity reduces confounding by off-target activity, enabling precise attribution of biological effects (internal article—this discussion incorporates detailed workflow integration advice not found in the linked overview).

Common Pitfalls or Misconceptions

• CP-673451 is ineffective against tumors driven primarily by VEGFR, EGFR, or TIE-2 signaling, as it shows minimal activity against these kinases at relevant concentrations (APExBIO).
• Micromolar concentrations are required for significant c-Kit inhibition, so it is not suitable for c-Kit-dependent models unless used at high, potentially nonselective doses.
• The compound is water-insoluble; improper formulation can lead to inconsistent dosing or precipitation in aqueous buffers.
• Long-term storage of solutions at room temperature leads to degradation; always store at -20°C or below.
• Observed in vivo effects may be confounded by poor solubility or stability if not prepared and stored according to manufacturer guidelines.

Workflow Integration & Parameters

CP-673451 (SKU: B2173) is supplied as a solid suitable for dissolution in DMSO (≥20.9 mg/mL) or ethanol (≥2.39 mg/mL with warming and ultrasonic treatment). For cell-based assays, serial dilution from DMSO stocks is recommended; the final DMSO concentration should not exceed 0.1% to prevent cytotoxicity. In vivo studies use oral dosing, with effective tumor PDGFR inhibition observed at 50 mg/kg in rat xenograft models. For angiogenesis inhibition, murine sponge models confirm efficacy at similar dosing regimens. Solutions should be prepared fresh or stored aliquoted below -20°C for several months. Consult the APExBIO product page for protocol-specific parameters and troubleshooting tips.

Conclusion & Outlook

CP-673451 is an essential tool for dissecting PDGFR-driven signaling in cancer research, offering nanomolar potency and high selectivity. Its utility is illustrated in xenograft and angiogenesis models, and especially in precision oncology settings such as ATRX-deficient gliomas. The compound’s well-characterized selectivity profile, validated storage and formulation guidelines, and reproducible efficacy benchmarks position CP-673451 as a reference standard for PDGFR inhibition studies. For comprehensive applications and updated experimental frameworks, researchers are encouraged to review related articles and product documentation from APExBIO.